CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
PEPN2113 COG A Phase 1 and pharmacokinetic study of Uproleselan (GMI-1271, IND #139758, NSC #801708) in combination with fludarabine and cytarabine for patients with acute myeloid leukemia, myelodysplastic syndrome or mixed phenotype acute leukemia that expresses E-selectin ligand on the cell membrane and is in second or greater relapse or that is refractory to relapse therapy Pediatric CIRB
PEPN2121 PEP-CTN A Phase 2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Pediatric CIRB
PEPN21EHR/PBTC-N15 Pediatric CITN Pilot Study to Enable Electronic Laboratory Data Transfer into Medidata Rave Pediatric CIRB
PEPN22P1 COG A Pharmacokinetic Study of VinCRIStine in Infants Dosed According to BSA-Banded Infant Dosing Tables Pediatric CIRB
PEPN2312 PEP-CTN A Phase 1 Study of GRN163L (Imetelstat) in Combination with Fludarabine and Cytarabine for Patients with Acute Myeloid Leukemia That Is in Second or Greater Relapse or That Is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or Is Refractory to Relapse Therapy Pediatric CIRB
PEPN2411 PEP-CTN DT2216 in combination with irinotecan for children, adolescents and young adults with relapsed or refractory solid tumors: a phase 1 study with phase 2 feasibility cohort for fibrolamellar carcinoma Pediatric CIRB
PEPN2415 PEP-CTN A Phase I study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of AZD1390 (NSC# 852149, IND# 172675) when combined with focal radiation in pediatric patients with High Grade Glioma Pediatric CIRB
RTOG-0126 RTOG A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer Adult CIRB - Late Phase Emphasis
RTOG-0129 RTOG A Phase III Trial of Concurrent Radiation and Chemotherapy (Followed by Surgery for Residual Primary/N2-3 Nodal Disease) for Advanced Head and Neck Carcinomas Adult CIRB - Late Phase Emphasis
RTOG-0214 RTOG A Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer Adult CIRB - Late Phase Emphasis